Thursday, 15 October 2026European Markets

AVANCE GAS HOLDING And FLEX LNG Have A High Dividend Yield And Return On Equity In The Oil & Gas Midstream Industry.

Loading stream...

(VIANEWS) - AVANCE GAS HOLDING (AGAS.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Oil & Gas Midstream industry.

Financial Asset Price Forward Dividend Yield Return on Equity
AVANCE GAS HOLDING (AGAS.OL) kr116.40 22.06% 17.24%
FLEX LNG (FLNG.OL) kr282.00 9.87% 16.13%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. AVANCE GAS HOLDING (AGAS.OL)

22.06% Forward Dividend Yield and 17.24% Return On Equity

Avance Gas Holding Ltd, together with its subsidiaries, engages in the transportation of liquefied petroleum gas (LPG) worldwide. The company transports LPG from the Middle East Gulf and the United States Gulf/the United States East Coast to destinations in Europe, South America, India, and Asia. As of December 31, 2023, it owned and operated through a fleet of fourteen very large gas carriers and six dual-fuel LPG newbuildings. Avance Gas Holding Ltd was founded in 2007 and is based in Hamilton, Bermuda. Avance Gas Holding Ltd is a subsidiary of Hemen Holding Ltd.

Earnings Per Share

As for profitability, AVANCE GAS HOLDING has a trailing twelve months EPS of kr40.77.

PE Ratio

AVANCE GAS HOLDING has a trailing twelve months price to earnings ratio of 2.86. Meaning, the purchaser of the share is investing kr2.86 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.24%.

More news about AVANCE GAS HOLDING.

2. FLEX LNG (FLNG.OL)

9.87% Forward Dividend Yield and 16.13% Return On Equity

Flex LNG Ltd., together with its subsidiaries, engages in the seaborne transportation of liquefied natural gas (LNG) worldwide. The company owns and operates vessels with M-type electronically controlled gas injection LNG carriers; and vessels with generation X dual fuel propulsion systems. Flex LNG Ltd. was incorporated in 2006 and is based in Hamilton, Bermuda.

Earnings Per Share

As for profitability, FLEX LNG has a trailing twelve months EPS of kr23.22.

PE Ratio

FLEX LNG has a trailing twelve months price to earnings ratio of 12.14. Meaning, the purchaser of the share is investing kr12.14 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.13%.

Moving Average

FLEX LNG's value is way under its 50-day moving average of kr322.15 and way below its 200-day moving average of kr335.96.

Volatility

FLEX LNG's last week, last month's, and last quarter's current intraday variation average was 0.30%, 0.03%, and 1.05%.

FLEX LNG's highest amplitude of average volatility was 1.11% (last week), 0.87% (last month), and 1.05% (last quarter).

More news about FLEX LNG.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com